Literature DB >> 19870541

THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : IV. THE PROZONE.

K Goodner1, F L Horsfall.   

Abstract

1. Type I antipneumococcus horse serum, in amounts exceeding a characteristic optimum, fails to protect mice against infection with the homologous type pneumococci. This failure is due to a marked inhibition of the phagocytic mechanism in the earlier stages of the infectious process. On the other hand, antipneumococcus rabbit serum in similar quantities does not inhibit phagocytosis, nor does it block the protection. 2. The experimental evidence suggests that the prozoning action of immune horse serum is due primarily to some characteristic property of the specific antibody and secondarily to an heterologous component of the serum, ineffective in itself but acting through the mediation of the antigen-antibody combination. This secondary factor may be a lipid.

Entities:  

Year:  1936        PMID: 19870541      PMCID: PMC2133425          DOI: 10.1084/jem.64.3.369

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  2 in total

1.  THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : I. THE QUANTITATIVE ASPECTS OF THE MOUSE PROTECTION TEST.

Authors:  K Goodner; F L Horsfall
Journal:  J Exp Med       Date:  1935-08-31       Impact factor: 14.307

2.  THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : II. THE COURSE OF THE INFECTIOUS PROCESS.

Authors:  K Goodner; D K Miller
Journal:  J Exp Med       Date:  1935-08-31       Impact factor: 14.307

  2 in total
  5 in total

1.  Cooperative binding mitigates the high-dose hook effect.

Authors:  Ranjita Dutta Roy; Christian Rosenmund; Melanie I Stefan
Journal:  BMC Syst Biol       Date:  2017-08-14

Review 2.  The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19.

Authors:  Arturo Casadevall; Liise-Anne Pirofski; Michael J Joyner
Journal:  mBio       Date:  2021-03-02       Impact factor: 7.867

3.  Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.

Authors:  Kerri Hagemann; Kristoffer Riecken; Johannes M Jung; Heike Hildebrandt; Stephan Menzel; Madeleine J Bunders; Boris Fehse; Friedrich Koch-Nolte; Fabian Heinrich; Sven Peine; Julian Schulze Zur Wiesch; Thomas T Brehm; Marylyn M Addo; Marc Lütgehetmann; Marcus Altfeld
Journal:  Eur J Immunol       Date:  2022-04-22       Impact factor: 6.688

4.  THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : V. THE EFFECT OF ADDED LIPIDS ON THE PROTECTIVE MECHANISM.

Authors:  K Goodner; F L Horsfall
Journal:  J Exp Med       Date:  1936-08-31       Impact factor: 14.307

5.  LIPIDS AND IMMUNOLOGICAL REACTIONS : IV. THE LIPID PATTERNS OF SPECIFIC PRECIPITATES FROM TYPE I ANTIPNEUMOCOCCUS SERA.

Authors:  F L Horsfall; K Goodner
Journal:  J Exp Med       Date:  1936-11-30       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.